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Summary
 
TRANCE (tumor necrosis factor [TNF]–related activation-induced cytokine) is a new mem-
ber of the TNF family that is induced upon T cell receptor engagement and activates c-Jun
N-terminal kinase (JNK) after interaction with its putative receptor (TRANCE-R). In addi-
tion, TRANCE expression is restricted to lymphoid organs and T cells. Here, we show that
high levels of TRANCE-R are detected on mature dendritic cells (DCs) but not on freshly
isolated B cells, T cells, or macrophages. Signaling by TRANCE-R appears to be dependent
on TNF receptor–associated factor 2 (TRAF2), since JNK induction is impaired in cells from
transgenic mice overexpressing a dominant negative TRAF2 protein. TRANCE inhibits apopto-
sis of mouse bone marrow–derived DCs and human monocyte-derived DCs in vitro. The re-
sulting increase in DC survival is accompanied by a proportional increase in DC-mediated T
cell proliferation in a mixed leukocyte reaction. TRANCE upregulates Bcl-x
 
L
 
 expression, sug-
gesting a potential mechanism for enhanced DC survival. TRANCE does not induce the pro-
liferation of or increase the survival of T or B cells. Therefore, TRANCE is a new DC-restricted
survival factor that mediates T cell–DC communication and may provide a tool to selectively
enhance DC activity.
 
A
 
poptosis plays a critical role in the development and
maintenance of the immune system (1–3). Members
of the TNF family can regulate apoptosis in addition to an
array of other biological effects such as cell proliferation
and differentiation (4). Despite the functional redundancy
of this family, specificity may be accomplished by coordi-
nating the spatial and temporal expression of TNF-related
ligands and their receptors and by restricting the expression
of signal transduction molecules to specific cell types. TNF
receptors interact with a family of molecules called TRAFs
(TNF receptor–associated factors) that act as adaptors for
downstream signaling events (5). For example, TRAF2 ac-
tivates NF-
 
k
 
B (6) and also c-Jun NH
 
2
 
-terminal kinase (JNK;
references 7–9). The biochemical events leading to apoptosis
involve the caspase family of cysteine proteases (10), whereas
NF-
 
k
 
B appears to inhibit cell death (11). The TNF recep-
tor family can also regulate apoptosis by modulating the ex-
pression of Bcl-2 and Bcl-2–related proteins (12, 13). Re-
cent data indicates that the Bcl-2 family controls apoptosis
by altering transmembrane conductance in mitochondria
and by preventing the activation of caspases (14–16).
An important role of TNF members in dendritic cell (DC)
biology has recently emerged. DCs have several specializa-
tions that lead to the stimulation of naive T cells and play a
role in the initiation of the immune response (17). TNF-
 
a
 
and CD40 ligand (L) are molecules involved in the differ-
entiation of DC from CD34
 
1
 
 bone marrow or cord blood
progenitors (18–20). Moreover, CD40L increases DC sur-
vival, upregulates MHC and costimulatory molecule expres-
sion, and induces the expression of a variety of cytokines (e.g.,
IL-12) in DCs (21). Both CD40 and TNFR interact with
TRAF2, suggesting that TRAF2 plays a role in DC function.
Recently, TRANCE (TNF-related activation-induced
cytokine), a novel ligand of the TNF family, was cloned dur-
ing a search for apoptosis regulatory genes (22). Remarkably,
TRANCE expression is restricted to lymphoid-specific or-
gans and is selectively expressed in T cells (22). In this study,
we describe that TRANCE-R signals via TRAF2 in thy-
mocytes and increases DC survival by upregulating Bcl-x
 
L
 
expression, a property shared with CD40L. However, un-
like CD40L, TRANCE selectively acts on mature DCs but
not on B cells. In addition, high levels of the TRANCE-R
are only detected on DCs, suggesting that a major function
of TRANCE in vivo is to modulate DC activity.
 
Brian R. Wong and Régis Josien contributed equally to this report.
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Materials and Methods
 
Expression and Purification of Soluble TRANCE.
 
A FLAG epitope-
tagged TRANCE molecule (FLAG-TRANCE) was expressed in
293T cells and purified as previously described (22). To create a
human CD8-TRANCE recombinant molecule (hCD8-TRANCE),
the extracellular domain of murine TRANCE (amino acid 245–
316) was fused to human CD8
 
a
 
 (amino acid 1–182) and pro-
duced in a baculovirus expression system according to the manu-
facturer’s instructions (BaculoGold; PharMingen, San Diego, CA).
hCD8-TRANCE was purified on cyanogen bromide (CNBR)-
activated Sepharose gel conjugated to OKT8 following the man-
ufacturer’s protocol (Pharmacia Biotech, Piscataway, NJ). mCD8-
CD40L in insect cell culture supernatant was provided by Dr.
Randolph J. Noelle (Dartmouth Medical School, Hanover, NH).
 
Mice.
 
C57BL/6 (H-2
 
b
 
) and BALB/c (H-2
 
d
 
) mice were from
Taconic Farms (Germantown, NY). Transgenic mice expressing
a dominant negative form of TRAF2 (TRAF2.DN) were engi-
neered as previously described (23).
 
Cells.
 
Bone marrow–derived DCs (BMDC) were generated
as previously described (24) and were used on day 8 of culture.
Enriched populations of fresh lymph node or splenic DCs were
prepared by digesting organs with collagenase then selecting for
low density cells via centrifugation on a Nycodenz column (14.5%
wt/vol in PBS 
 
1
 
 5 mM EDTA; Nycomed Pharmaceuticals, Oslo,
Norway) for 15 min at 4
 
8
 
C. Mature spleen DCs were prepared
by culturing freshly isolated spleen DCs overnight as previously
described (25). The cytokine-induced generation of human DCs
from PBMCs was performed as previously described (26). After 2 d
in monocyte-conditioned medium, TRANCE or PBS was added
to the DCs. Lymph node T cells (99% CD3
 
1
 
 as assessed by flow
cytometry) were prepared by magnetic bead depletion (Dynal, Oslo,
Norway) of class II, B220, NK1.1, and F4/80 positive cells. B cells
were prepared by magnetic depletion of Thy1.2 positive cells
(Dynal). Cell viability was assayed by trypan blue exclusion or by
propidium iodide uptake.
 
Flow Cytometry.
 
DC phenotype was assessed by flow cytom-
etry as previously described (27) using the following FITC- or
PE-conjugated mAbs: H-2K
 
b
 
, I-A
 
b
 
, intracellular adhesion mole-
cule (ICAM)-1, CD11b, CD11c, CD80, CD86, CD25, and CD40
(all from PharMingen). Other mAbs used were biotinylated 
 
a
 
-Fas,
CD3-FITC, B220-FITC (PharMingen), and NLDC-145–FITC.
The expression of TRANCE-R was assessed using the hCD8-
TRANCE fusion molecule at 10 
 
m
 
g/ml at 4
 
8
 
C followed by bi-
otinylated OKT8 mAb and then streptavidin-PE (BioSource In-
ternational, Camarillo, CA). Negative controls were performed
by omitting hCD8-TRANCE. For analysis of TRANCE-R ex-
pression on resting B cells and fresh DCs, low density cells were
stained with FITC-B220 or FITC-CD11c, respectively, and ana-
lyzed on a FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA).
 
Mixed Leukocyte Reaction.
 
BMDCs treated for 48 h in the
presence or absence of recombinant TRANCE were cultured with
10
 
5
 
 purified allogeneic T cells in flat-bottomed 96-well plates in a
final volume of 200 
 
m
 
l for 3 d and then pulsed for 8 h with 0.5
 
m
 
Ci of [
 
3
 
H]thymidine (Dupont-NEN, Boston, MA). The cells
were then harvested on glass fiber filters and [
 
3
 
H]thymidine in-
corporation was measured using a standard scintillation-detection
procedure.
 
JNK Assays.
 
2–5 
 
3
 
 10
 
6
 
 cells from TRAF2.DN transgenic
mice or from control littermates were incubated for 1–2 h at 37
 
8
 
C
on plates coated with OKT8 antibody (10 
 
m
 
g/ml). The cells were
treated with either soluble TRANCE or an equal volume of PBS
before being harvested at the indicated time points and frozen in a
dry ice/ethanol bath. JNK was immunoprecipitated with 
 
a
 
-JNK1
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and kinase
activity was assessed as previously described (22).
 
Western Blot and Reverse Transcriptase–PCR Analysis of Bcl-x
 
L
 
and Bcl-2.
 
BMDCs (8 
 
3
 
 10
 
6
 
/well) were cultured in RPMI in
6-well plates and treated with PBS, FLAG-TRANCE (1 
 
m
 
g/ml),
or soluble CD40L for 0 or 24 h. The cells were lysed, and 50 
 
m
 
g
of protein from each sample was resolved on a 12% SDS-PAGE
gel and transferred to Immobilon-P membranes (Millipore, Bed-
ford, MA). The blots were blocked in 5% skim milk, probed with
 
a
 
-Bcl-2 (4C11) or 
 
a
 
-Bcl-x
 
L
 
 (236; both provided by Dr. Gabriel
Núñez, University of Michigan, Ann Arbor, MI) and detected
with the appropriate horseradish peroxidase–conjugated second-
ary antibodies and enhanced chemiluminesence substrate (ECL;
Amersham Corp., Arlington Heights, IL). For reverse transcriptase–
PCR  analysis of 
 
bcl-x
 
L
 
 mRNA expression, BMDCs (2 
 
3
 
 10
 
6
 
cells/well) were cultured in 24-well plates, treated with the ap-
propriate reagents, and quickly frozen in a dry ice/ethanol bath at
the various time points. Total RNA was extracted (RNEasy;
QIAGEN Inc., Chatsworth, CA), and cDNA was diluted to al-
low PCR amplification to occur as a linear function of starting
concentrations. PCR was performed using the conditions and
primers as previously described (13).
 
Results and Discussion
 
TRANCE-R Is Expressed at High Levels in DCs.
 
To iden-
tify cells that express TRANCE-R, hCD8-TRANCE was
used as a molecular probe for FACS
 
Ò
 
 analysis. TRANCE-R
was detected on mature BMDCs, freshly isolated lymph node
DCs, and freshly isolated spleen DCs (Fig. 1). TRANCE-R
was greatly upregulated upon the maturation of spleen DCs
induced by overnight culture. No expression could be de-
tected on freshly isolated lymph node B cells, lymph node
T cells, thymocytes, or peritoneal macrophages. Therefore,
the highest levels of TRANCE-R expression are found on
mature DCs and suggest that the major role of TRANCE
is restricted to DCs.
 
TRANCE Is a DC Survival Factor.
 
The biological ef-
fects of TRANCE were further studied on mature DCs.
TRANCE-treated DCs formed densely packed clusters
whereas control, untreated cells exhibited relatively sparse
aggregates (Fig. 2 
 
A
 
). In addition, mature BMDCs treated
with FLAG-TRANCE were significantly protected from
spontaneous cell death compared to untreated cells. This
effect was dependent on the dose of TRANCE (Fig. 2 
 
B
 
).
hCD8-TRANCE elicited similar results (data not shown).
This effect was not due to increased cell proliferation since
the total number of cells remained the same over time (data
not shown). TRANCE significantly prevented DC cell death
until day 6, whereas untreated cells were almost completely
dead by day 3 (Fig. 2 
 
C
 
). A similar effect on DC survival
was observed with human monocyte-derived DC (Fig. 2 
 
D
 
).
Confirming previous data, CD40L also induced the clus-
tering of DCs (data not shown; 28, 29) and enhanced DC
survival comparably to TRANCE (Fig. 2 
 
C
 
).
CD40L upregulates the antiapoptotic molecule, Bcl-x
 
L
 
,
in B cells and protects them from Ig receptor–mediated cell
death (13). In addition, CD40L upregulates Bcl-2 in hu- 
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man DC derived from CD34
 
1
 
 progenitor cells, a phenom-
enon that was correlated with a resistance to Fas-mediated
apoptosis (12). To determine whether TRANCE can influ-
ence Bcl-2 or Bcl-x
 
L
 
, we measured their expression in DCs
stimulated with TRANCE or CD40L by Western blot anal-
ysis. BMDCs expressed relatively high levels of Bcl-2 and
relatively low levels of Bcl-x
 
L
 
 after reaching maturity in GM-
CSF (Fig. 2 
 
E
 
, 0 h). FLAG-TRANCE and CD40L stimu-
lation lead to increased Bcl-x
 
L
 
 expression by 24 h. Bcl-x
 
L
 
expression was nearly absent in cells treated with medium
alone. 
 
bcl-x
 
L
 
 mRNA was upregulated in TRANCE-treated
DCs, suggesting a transcriptional as opposed to posttran-
scriptional regulation (data not shown). In contrast, Bcl-2
levels were decreased in both the TRANCE-treated and
untreated cells (Fig. 2 
 
E
 
). These results suggest that
TRANCE, in addition to CD40L, upregulates Bcl-x
 
L
 
 in
DCs, which enhances their viability in vitro.
 
TRANCE Enhances DC-mediated T Cell Proliferation.
 
To examine the functional consequences of TRANCE on
DCs we measured the MLR-stimulating ability of DCs
treated with TRANCE. Increasing doses of FLAG-
TRANCE enhanced DC survival at 48 h, which in turn
led to a proportional increase in the stimulation of T cell
proliferation (Fig. 3 
 
A
 
). When equivalent numbers of via-
ble TRANCE-treated or untreated DCs were used in an
MLR, there were no differences in T cell proliferation,
suggesting that changes in the expression of costimulatory
and antigen-presenting molecules did not account for the
enhanced T cell proliferation (Fig. 3 
 
B
 
). To verify this, the
levels of several surface markers were tested by FACS
 
Ò
 
 to
evaluate any TRANCE-mediated changes to the DC phe-
notype. There was a slight but reproducible downregulation
of MHC class II expression and a slight upregulation of MHC
Figure 1. TRANCE-R expression in various cell types. Cells were prepared as described in the Materials and Methods section and stained with 10
mg/ml of the hCD8-TRANCE recombinant protein (solid lines) or with secondary reagents alone (dotted line). Only viable cells as determined by propid-
ium iodide (PI) exclusion were gated and analyzed for TRANCE-R expression. Fresh DCs were analyzed by two-color staining after gating on
CD11chigh cells. Each staining was reproduced at least twice.
 
Figure 2.
 
TRANCE is a DC survival factor that upregulates Bcl-x
 
L
 
.
(
 
A
 
) BMDCs were cultured in complete medium in the presence or ab-
sence of recombinant TRANCE (1 
 
m
 
g/ml) for 48 h and were then visu-
alized under an inverted light microscope. (
 
B
 
) Duplicate wells containing
3 
 
3
 
 10
 
4
 
 BMDCs were cultured with increasing doses of recombinant
TRANCE in complete medium in flat-bottomed 96-well plates. The
percentage of cell survival was assessed 48 h later by trypan blue exclusion.
The average of three experiments, and the SEMs, are shown. (
 
C
 
) 3 
 
3
 
 10
 
4
 
BMDCs were cultured in complete medium in the presence or absence of
 
recombinant TRANCE (1 
 
m
 
g/ml) or mCD8-CD40L (1/1,000 of the
culture supernatants). Cell viablity was assessed daily by trypan blue ex-
clusion. Representative data of three independent experiments are shown.
(
 
D
 
) 3 
 
3
 
 10
 
4
 
 GM-CSFs and IL-4 stimulated human monocyte-derived
DCs were cultured for 2 d in monocyte conditioned medium to generate
mature DCs (26). Thereafter, DCs were cultured in the presence or ab-
sence of recombinant TRANCE (1 
 
m
 
g/ml) and cell viability was assessed
each day by trypan blue exclusion. (
 
E
 
) 50 
 
m
 
g of protein extracted from
BMDCs that had been cultured for 24 h as described in Fig. 2 
 
C
 
 were an-
alyzed for Bcl-2 and Bcl-x
 
L
 
 protein expression by Western blot analysis.
Basal levels of Bcl-2 and Bcl-x
 
L
 
 were determined in day 8 BMDCs (
 
0 h
 
). 
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class I expression (Fig. 3 
 
C
 
). There were no TRANCE-
mediated perturbations in the expression of the costimulatory
molecules CD80 (B7-1) or CD86 (B7-2), and no changes
in the expression of the adhesion molecules intracellular
adhesion molecule (ICAM)–1, CD11b, and CD11c. Inter-
estingly, CD40 expression increased but Fas and TRANCE-R
did not. In sum, TRANCE enhances DC-mediated T cell
proliferation by increasing the survival of DCs.
 
TRANCE Does Not Affect B or T Cell Proliferation.
 
Expres-
sion of high levels of the TRANCE-R appeared restricted
to DCs by FACS
 
Ò
 
 analysis. However, we found that
TRANCE could activate JNK in thymocytes (22), sug-
gesting that FACSÒ analysis might lack the sensitivity to
detect low levels of receptor. To further examine the spec-
ificity of TRANCE for DCs, we tested its ability to induce
B cell proliferation or survival, two functions mediated by
CD40L. Recombinant hCD8-TRANCE, tested for its an-
tiapoptotic function in BMDCs, could not stimulate B cell
proliferation (Fig. 4), nor could it activate JNK activation
(22). In contrast, CD40L efficiently stimulated B cell pro-
liferation in a dose-dependent manner (Fig. 4). Finally,
TRANCE could not prevent the spontaneous apoptosis of
B and T cells as assessed by propidium iodide uptake (data
not shown). Therefore, functionally, TRANCE appears to
exhibit different cellular specificities and functions when
compared to CD40L.
TRANCE-mediated JNK Induction Requires Functional
TRAF2. Recruitment of TRAF2 to the TNFR complex
or the CD40 receptor complex is necessary for JNK activa-
tion (7–9, 23). To test the possibility that TRANCE-R
also signals via TRAF2, we analyzed TRANCE-mediated
JNK activation in thymocytes from transgenic mice over-
expressing a dominant negative form of TRAF2 (TRAF2.
DN; reference 23). JNK activity peaked 2.5-fold over un-
stimulated cells at 5 min in control littermates, whereas JNK
induction was significantly reduced in TRAF2.DN thymo-
cytes (Fig. 5). These results suggest that signaling from the
TRANCE-R requires TRAF2. TRANCE-mediated JNK
induction in DCs could not be assayed since TRAF2.DN
expression has been restricted to lymphocytes in the
TRAF2.DN transgenic mice. In addition, JNK activity was
constitutively high in mature DCs (22), which are also
known to have high levels of activated NF-kB (30), thus
confounding detection of increased JNK activity.
In summary, we have shown that TRANCE, in addition
to CD40L, is a regulator of DC function. Similar to
CD40L, TRANCE promotes the survival of mature DCs
by regulating the expression of Bcl-xL. However, in con-
trast to CD40L, TRANCE does not act on other APCs such
as B cells. The signal transduction pathways via TRANCE-R
in DCs are unknown. TRANCE appears to signal via
TRAF2, at least in thymocytes, suggesting that TRAF2
Figure 3. Cell surface marker expression and T cell stimulatory func-
tion of TRANCE-treated BMDCs. (A) 2.5 3 103 BMDCs were cultured
with increasing doses of TRANCE in a final volume of 100 ml in tripli-
cate in flat-bottomed 96-well plates. After 48 h, 105 purified allogeneic T
cells in 100 ml were added in each well and [3H]thymidine incorporation
was assessed after 3 d of culture. One experiment out of three is shown.
(B) 2.5 3 104 BMDCs were cultured in the presence or absence of
TRANCE or CD40L for 48 h. After washing and counting the cells, di-
lutions of live cells were cultured with 105 purified allogeneic T cells and
[3H]thymidine incorporation was assessed after 3 d of culture. (C) BMDCs
were cultured in complete medium for 24 h in the presence (solid lines) or
absence (dotted lines) of soluble FLAG-TRANCE (1 mg/ml) and analyzed
for the indicated surface markers expression by FACSÒ after gating the
live cells. Similar results were obtained after 48 h of culture.
Figure 5. TRANCE-R sig-
naling is dependent on TRAF2.
Thymocytes from transgenic
mice expressing TRAF2.DN or
control littermates were stimu-
lated with hCD8-TRANCE (1
mg/ml) on OKT8-coated (10
mg/ml) plates for the indicated
amount of time then assayed for
JNK activity. The degree of JNK
activation was analyzed on a phos-
phorimager  (Molecular Imager
System; Bio-Rad Laboratories,
Hercules, CA) and plotted as
fold induction over time 0. Rep-
resentative results of three inde-
pendent experiments are shown.
Figure 4. TRANCE does
not induce the proliferation of B
or T cells. Triplicate wells of 2 3
104 purified B cells were cultured
in complete medium in the pres-
ence of increasing doses of soluble
TRANCE or CD40L in flat-bot-
tomed 96-well plates. 105 purified
T cells were cultured in complete
medium containing Con A (2.5
mg/ml) in the presence of increas-
ing doses of soluble TRANCE.
[3H]thymidine incorporation was
assessed after 2 d of culture.2079 Wong et al. Brief Definitive Report
may play a critical role in mediating signals for differentia-
tion, activation, and survival in DCs.
These findings complement our previous report describ-
ing the selective expression of this new TNF family mem-
ber in T cells. The high level of expression of TRANCE-R
on DCs suggests a specific role for TRANCE in T cell–DC
communication during the primary immune response. Rapid
upregulation of TRANCE upon TCR engagement on T
cells (22) could specifically enhance the survival of DCs
during antigen presentation. Both antigen-specific T cells
and the antigen-presenting DCs would therefore depend
on each other for activation and survival. Mature DCs that
fail to present antigen to T cells would not receive T cell
help and would therefore die of neglect. This T cell–DC
interaction is likely to occur in the T cell area of lymphoid
organs that contain DCs of mature phenotypes (31). DCs can
only be detected in afferent lymph, not efferent lymph, sug-
gesting that DCs are destined to die when they migrate to
the lymph node. TRANCE may be important to maintain
DC survival, perhaps acting before CD40L as TRANCE is
an immediate early gene (22). Many experiments indicate that
DCs pulsed ex vivo with antigen can be used to induce im-
munity to tumor or viral antigens in vivo (32). TRANCE
could provide a tool to specifically enhance DC function
by enhancing their survival in vivo. This hypothesis is cur-
rently being examined in a variety of viral and tumor mod-
els in mice.
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